The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Xinan, Ma, Jun, Knight, Tristan, Su, Yongwei, Edwards, Holly, Polin, Lisa, Li, Jing, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Wang, Jian, Lin, Hai, Wang, Yue, Wang, Liping, Wang, Guan, Taub, Jeffrey W., Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184771/
https://www.ncbi.nlm.nih.gov/pubmed/34099621
http://dx.doi.org/10.1038/s41408-021-00502-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184771/
https://www.ncbi.nlm.nih.gov/pubmed/34099621
http://dx.doi.org/10.1038/s41408-021-00502-7

Ejemplares similares